All In Biotech

Drug Trial Radar · NCT00323817

To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia

Last checked: Nov 19, 2026Latest source record: May 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 282 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

282

Planned (sponsor's estimate)

Start

Apr 2006

Primary completion

Apr 2009

Study completion Oct 2009

Sponsor

Lead sponsor
Zeria PharmaceuticalIndustry
Sponsor type
Industry
First posted
May 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of Z-338 in subjects with Functional Dyspepsia

Conditions

  • Functional Dyspepsia

Interventions

  • Z-338Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global subject Outcome AssessmentTime frame: 12 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Leuven University

    Leuven, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.